A group of researchers, including oncologists and data scientists, from the University of Florida and Indiana University hypothesized that GLP-1s hold promise in oncology due to their ability to lower glucose, adiposity, insulin resistance, and systemic inflammation factors associated with cancer progression, according to a July 2025 paper published in JAMA
These trials showed that Retatrutides activation of GLP-1, GIP, and glucagon receptors can improve metabolic balance, enhance fat oxidation, and support weight management outcomes in study populations
Tampoco debe tomarse con el estmago vaco.
Jensterle Sever, M., Kocjan, T., Pfeifer, M., Kravos, N
F.Pulido-CriolloF
Regular monitoring of weight, HbA1c (for diabetes patients), and treatment tolerability is essential to ensure safe and effective use